First time unlucky for Australian listing of Pharmaxis' cystic fibrosis drug
This article was originally published in Scrip
Executive Summary
Pharmaxis' first attempt at getting its cystic fibrosis therapy Bronchitol (mannitol) included in Australia's reimbursement scheme has been unsuccessful, although the company remains confident it will be eventually be covered.